Since May 1st Malin Hultqvist Hopkins,
former CSO, is appointed CEO of Redoxis. This change is in line with Redoxis continuous ambition to be a
focused and efficient CRO specialising on preclinical autoimmune and inflammatory models in vitro and in vivo.
Former CEO, Peter Olofsson, is since
April 1st CEO of Redoxis R&D focused subsidiary ProNoxis AB and will continue late stage preclinical
development of therapies for severe and rare autoimmune diseases.
This is a result from a strategic
decision, anticipated to be beneficial for both companies with more focused and engaged
Naturally, we will maintain strong collaboration and synergistic
R&D capacities between the companies.